A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck.

Abstract

This double-blind, vehicle-controlled, multicenter study evaluated the efficacy and safety of a new topical antineoplastic agent, masoprocol, in the treatment of actinic keratoses of the head and neck. Of the 113 patients who applied topical masoprocol twice a day for 14 to 28 days, there was a mean decrease in actinic keratoses from 15.0 to 5.4 and a median percent reduction from baseline actinic keratosis count of 71.4% at the 1-month follow-up visit. Comparable numbers for the vehicle-treated group were 13.4 to 11.1 actinic keratoses and 4.3% median percent reduction. Irritation, as manifested by erythema or flaking, occurred in 61.5% of topical masoprocol-treated patients versus 26.7% of those treated with vehicle and did not correlate with clinical response. Topical masoprocol appears to be useful in the treatment of actinic keratoses.

• Authors: E A Olsen, M L Abernethy, C Kulp-Shorten, J P Callen, S D Glazer, A Huntley, M McCray, A B Monroe, E Tschen, J E Wolf Jr
• Journal: Journal of the American Academy of Dermatology (J Am Acad Dermatol) Vol. 24 Issue 5 Pt 1 Pg. 738-43 (May 1991) ISSN: 0190-9622 [Print] United States
• PMID: 1869646 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Ointments
• Masoprocol

Topics

• Administration, Cutaneous
• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Clinical Protocols
• Double-Blind Method
• Facial Dermatoses (drug therapy, pathology)
• Female
• Head
• Humans
• Keratosis (drug therapy, pathology)
• Male
• Masoprocol (administration & dosage, adverse effects, therapeutic use)
• Middle Aged
• Ointments